top of page
Prevalence of high probability of PH in early systemic sclerosis
In patients with early systemic sclerosis or systemic sclerosis without cutaneous involvement, 26% had a high probability of pulmonary hypertension (PH), most often pulmonary arterial hypertension. Screening for pulmonary hypertension early in the course of systemic sclerosis may help identify PH sooner. Read the Revista Colombiana de ReumatologĂa (English edition) article
Robyn Kalda
1 day ago1 min read
Â
Â
Â
Systematic review of treatment strategies to reach low-risk status in PH
A systematic review examined the evidence linking individual pulmonary hypertension treatment strategies to low-risk status and long-term outcomes. 48 reports were included. Few patients reached low-risk status. Prostacyclin pathway therapy and add-on sotatercept improved clinical outcomes. Low-risk status predicted survival, but people initially at low risk did not often stay low risk: the risk category at their first annual review predicted the later disease course. Studies
Robyn Kalda
Nov 91 min read
Â
Â
Â
Using antithrombotics in children with PH
A study used US registry data and a survey to explore the usage of antithrombotic therapy in children with pulmonary hypertension (PH). Antithrombotic therapy is used infrequently in pediatric PH and is primarily reserved for high-risk patients, with significant variation across centers. Survey data generally agreed that antithrombotic therapy was not indicated for patients at the lowest risk and was probably indicated for patients at the highest risk, but management of inter
Robyn Kalda
Nov 21 min read
Â
Â
Â
Selexipag side effects are associated with hemodynamic responses
A Japanese study examined whether selexipag side effects were associated with hemodynamic responses and found that headaches might be associated with treatment responsiveness and a better prognosis through mPAP reduction. Read the Therapeutic Advances in Respiratory Disease article
Robyn Kalda
Oct 261 min read
Â
Â
Â
Patient and Clinician Views on Shared Decision-Making
Preference for shared decision-making was nearly universal among patients and clinicians. However, priorities differed significantly. Patients more frequently emphasized quality of life (81% vs. 54%) and efficacy of therapy (42% vs. 29%), whereas clinicians prioritized risk of disease progression (67% vs. 30%). Although 92% of clinicians reported eliciting patient values, only 75% of patients perceived that this occurred. There is a discordance in treatment priorities betwe
Robyn Kalda
Oct 211 min read
Â
Â
Â
Why lived experience must shape research
"Drawing on decades of patient advocacy, two women living with the rare condition Congenital Melanocytic Naevus argue that lived experience must shape research from the outset, and discuss how genuine patient-researcher partnership transforms science, care and identity." Read the PLOS Medicine article
Robyn Kalda
Oct 191 min read
Â
Â
Â
More than half of pulmonary fibrosis patients have PH
There is not much data looking at pulmonary hypertension (PH) in interstitial lung disease, except in idiopathic pulmonary fibrosis (IPF). A study of patients with pulmonary fibrosis found that 60.7% of those with progressive pulmonary fibrosis (PPF) and 63.8% of those with idiopathic pulmonary fibrosis had pulmonary hypertension. Read the Respiratory Investigation article
Robyn Kalda
Oct 121 min read
Â
Â
Â
Frequent imaging of children with PH may lead to high radiation doses
A 41-study review of children with non-cancer chronic diseases looked at how much radiation they were exposed to during their relatively frequent medical imaging. Children with PH were included. The review found that plain x-rays did not lead to significant radiation accumulation, but CT scans and flouroscopy led to much higher accumulation. Read the review in Pediatric Radiology
Robyn Kalda
Oct 51 min read
Â
Â
Â
What affects physical activity for people with PH?
A UK study examined the factors that affected physical activity participation among people with pulmonary hypertension (PH). They found four themes: fear of breathlessness; lack of motivation and a desire for monitoring and targets; keeping up appearances; and receiving little advice on physical activity, so they had to initiate communication themselves. The researchers suggest that broadening people's idea of what physical activity is, alongside goal-setting and deliberate m
Robyn Kalda
Sep 281 min read
Â
Â
Â
Why men with systemic sclerosis-associated PAH fare worse
Men with systemic sclerosis and pulmonary arterial hypertension (PAH) tend to have more heart-related complications and lower survival rates. Differences in the effects of hormones such as estrogen and testosterone may play a role. These findings underscore the importance of identifying higher-risk men early and developing treatment approaches better suited to their needs. Read the Clinical Medicine Insights: Cardiology article
Robyn Kalda
Sep 211 min read
Â
Â
Â
First two patients enrolled in a clinical trial to treat Group 2 PH
A press release announced that the first two patients have enrolled in a trial of a treatment for Group 2 pulmonary hypertension (PH associated with left heart disease). The treatment procedure is minimally invasive and aims to reduce overactive nerve signals that might contribute to changes in the blood vessels in the lungs and to worsening heart and lung disease. Earlier studies confirmed that the procedure was safe and showed potential benefits. This procedure is also bein
Robyn Kalda
Sep 141 min read
Â
Â
Â
Animal research shows miR-224 contributes to PAH
A small molecule called microRNA-224-5p (miR-224) appears to play an important role in the changes to the lung blood vessels that occur in pulmonary arterial hypertension (PAH). Researchers found that miR-224 levels were higher in cells from people with PAH and in several animal models, and that increasing miR-224 worsened the disease. In contrast, blocking miR-224 reduced abnormal blood vessel changes and improved right heart function in mice and rats. The researchers believ
Robyn Kalda
Sep 81 min read
Â
Â
Â
Dual PH therapy before BPA lowers complications
Researchers found that pre-treating pulmonary hypertension (PH) patients with dual therapy before they underwent balloon pulmonary angioplasty was associated with lower complications and better clinical outcomes, compared to mono therapy. Read the CHEST article
Robyn Kalda
Aug 311 min read
Â
Â
Â
Advances in subcutaneous infusion pump therapy for PAH
Infusion pump technology for subcutaneous prostacyclin analog therapy has improved, with improved user experiences, simplified priming processes, easier filling, capability for lower doses, and better safety alerts and alarms. This may allow more pulmonary arterial hypertension (PAH) patients to safely manage and benefit from subcutaneous prostacyclin analogs. Read the Advances in Therapy commentary
Robyn Kalda
Aug 241 min read
Â
Â
Â
SPP1 improves risk assessment for pregnant people with PAH
Secreted phosphoprotein 1 (SPP1) levels were higher in patients with PAH, and SPP1 levels were associated with disease severity. Patients who had postpartum adverse events had higher SPP1 concentrations. SPP1 may act as a predictor of adverse postpartum events for people with pulmonary arterial hypertension (PAH), along with other clinical indicators. Read the European Journal of Obstetrics and Gynecology and Reproductive Biology article
Robyn Kalda
Aug 171 min read
Â
Â
Â
In PAH, palliative care discussions need to be proactive
A survey of 200 people in the United States living with pulmonary arterial hypertension (PAH) found that 85% had never discussed palliative care with their healthcare provider, even though nearly nine in 10 said they would feel comfortable doing so. Many participants mistakenly thought palliative care was only for end-of-life care, highlighting the need for better conversations so people understand how it can help manage symptoms and improve quality of life throughout their i
Robyn Kalda
Aug 101 min read
Â
Â
Â
Endoplasmic reticulum stress induces a pathway that accelerates PAH progression
This study found that endoplasmic reticulum stress in lung blood vessels may contribute to pulmonary arterial hypertension (PAH) by triggering pyroptosis and damaging blood vessels. In rats, blocking this process reduced blood vessel damage and slowed the development of PAH. Read the Journal of the American Heart Association article
Robyn Kalda
Aug 31 min read
Â
Â
Â
Phase 3 ADVANCE OUTCOMES trial on ralinepag succeeds
Patients with pulmonary arterial hypertension who took ralinepag in addition to their usual treatment were less likely to have their disease get worse than those who took a placebo. However, more people stopped taking ralinepag because of side effects. Read the Lancet article
Robyn Kalda
Jul 291 min read
Â
Â
Â
More severe functional limitations are associated with higher social isolation
Functional disability, but not chronic disease category or chronic pain, was independently associated with lower social support. Social isolation among Canadian adults is more closely associated with functional limitations than with diagnostic labels, underscoring the importance of function-focused approaches in research and intervention. Read the Health Promotion and Chronic Disease Prevention Journal article
Robyn Kalda
Jul 271 min read
Â
Â
Â
Smartphone data can support earlier detection of PAH
Researchers looked at smartphone data from 109 participants in the UK. Software was trained to distinguish idiopathic pulmonary hypertension (IPAH) and did so correctly at least 75% of the time. This suggests metrics from wearable tech can complement traditional risk assessment and may support earlier PAH detection. Read the NPJ Cardiovascular Health article
Robyn Kalda
Jul 201 min read
Â
Â
Â
bottom of page
